Skip to main content

Advertisement

Table 1 Patient demographics and baseline characteristics

From: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study

Characteristics AL dispersible (n = 227) DP paediatric (n = 227) p value*
Age (months)  29.6 (15.2)  32.0 (14.9) 0.094
Weight (kg)  12.2 (3.2)  12.3 (3.2) 0.709
Temperature (°C)  38.3 (1.0)  38.3 (2.1) 0.949
Parasite density (/μL), mean (95% CI) 38,202.2 (32,180.0 to 45,351.3) 38,545.7 (32,615.8 to 45,553.8) 0.941
Haemoglobin (g/dL)  9.2 (1.9)  9.4 (2.0) 0.293
White blood cells (x103/μL)  9.9 (4.5)  9.5 (3.8) 0.258
Platelets (x103/μL) 134.8 (66.1) 134.9 (67.1) 0.988
Red blood cells (x106/μL)  3.7 (0.9)  3.7 (0.8) 0.764
Neutrophils (%)  41.0 (17.5)  43.1 (17.8) 0.203
Lymphocytes (%)  50.6 (17.2)  48.4 (17.5) 0.182
Monocytes (%)  7.4 (3.0)  7.6 (4.9) 0.559
  1. Data are mean (±SD) unless otherwise specified. AL: Artemether-lumefantrine; DP: dihydroartemisinin-piperaquine; *p value from t-test or Mann–Whitney test; Geometric mean with its 95% CI; p value from t-test on the log parasite density.